Avian influenza A (H5N1) virus infection

Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261-273.Full text external link opens in a new windowAbstract external link opens in a new window

World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. February 2010 [internet publication].Full text external link opens in a new window

World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. June 2006 [internet publication].Full text external link opens in a new window

Centres for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. March 2017 [internet publication].Full text external link opens in a new window

World Health Organization. Infection control recommendations for avian influenza in health-care facilities. 2006 [internet publication].Full text external link opens in a new window

Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. February 2018 [internet publication].Full text external link opens in a new window

1. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333-340.Full text external link opens in a new windowAbstract external link opens in a new window

2. Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet. 2008;371:1427-1434.Abstract external link opens in a new window

3. Skowronski DM, Tweed SA, Petric M, et al. Human illness and isolation of low-pathogenicity avian influenza virus of the H7N3 subtype in British Columbia, Canada. J Infect Dis. 2006;193:899-900.Abstract external link opens in a new window

4. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet. 1999;354:916-917.Abstract external link opens in a new window

5. Uyeki TM, Chong YH, Katz JM, et al. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis. 2002;8:154-159.Full text external link opens in a new windowAbstract external link opens in a new window

6. Eurosurveillance editorial team. Avian influenza A/(H7N2) outbreak in the United Kingdom. Euro Surveill. 2007;12:pii=3206.Full text external link opens in a new windowAbstract external link opens in a new window

7. Kurtz J, Manvell RJ, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 1996;348:901-902.Abstract external link opens in a new window

8. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004;10:2196-2199.Full text external link opens in a new windowAbstract external link opens in a new window

9. Nguyen-Van-Tam JS, Nair P, Acheson P, et al. Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis. Euro Surveill. 2006;11:pii=2952.Full text external link opens in a new windowAbstract external link opens in a new window

10. Pan M, Gao R, Lv Q, et al. Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect. 2016;72:52-59.Abstract external link opens in a new window

11. Yang ZF, Mok CK, Peiris JS, et al. Human infection with a novel avian influenza A (H5N6) virus. N Engl J Med. 2015;373:487-489.Full text external link opens in a new windowAbstract external link opens in a new window

12. World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization H5N1 Evolution Working Group. Revised and updated nomenclature for highly pathogenic avian influenza A (H5N1) viruses. Influenza Other Respir Viruses. 2014;8:384-388.Full text external link opens in a new windowAbstract external link opens in a new window

13. World Health Organization. Evolution of the influenza A(H5) haemagglutinin: WHO/OIE/FAO H5 Working Group reports a new clade designated 2.3.4.4. January 2015 [internet publication].Full text external link opens in a new window

14. Smith GJ, Donis RO; World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization (WHO/OIE/FAO) H5 Evolution Working Group. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014. Influenza Other Respir Viruses. 2015;9:271-276.Full text external link opens in a new windowAbstract external link opens in a new window

15. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines: February 2010. Wkly Epidemiol Rec. 2010;85:100-107.Full text external link opens in a new window

16. Nguyen T, Rivailler P, Davis CT, et al. Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010. Virology. 2012;432:405-416.Abstract external link opens in a new window

17. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261-273.Full text external link opens in a new windowAbstract external link opens in a new window

18. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2010. Wkly Epidemiol Rec. 2011;86:161-166.Full text external link opens in a new windowAbstract external link opens in a new window

19. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis. 2009;49:279-290.Full text external link opens in a new windowAbstract external link opens in a new window

20. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005;352:686-691.Full text external link opens in a new windowAbstract external link opens in a new window

21. Rajabali N, Lim T, Sokolowski C, et al. Avian influenza A (H5N1) infection with respiratory failure and meningoencephalitis in a Canadian traveller. Can J Infect Dis Med Microbiol. 2015;26:221-223.Full text external link opens in a new windowAbstract external link opens in a new window

22. Kandeel A, Manoncourt S, Abd el Kareem E, et al. Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006-2009. Emerg Infect Dis. 2010;16:1101-1107.Full text external link opens in a new windowAbstract external link opens in a new window

23. International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). Outbreak of mild respiratory disease caused by H5N1 and H9N2 infections among young children in Dhaka, Bangladesh, 2011. Health Sci Bulletin. 2011;9:1-12.Full text external link opens in a new window

24. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis. 2012;55:26-32.Full text external link opens in a new windowAbstract external link opens in a new window

25. Shinde V, Hanshaoworakul W, Simmerman JM, et al. A comparison of clinical and epidemiological characteristics of fatal human infections with H5N1 and human influenza viruses in Thailand, 2004-2006. PLoS One. 2011;6:e14809.Full text external link opens in a new windowAbstract external link opens in a new window

26. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2018 [internet publication].Full text external link opens in a new window

27. World Health Organization. Update: WHO-confirmed human cases of avian influenza A (H5N1) infection, November 2003-May 2008. Wkly Epidemiol Rec. 2008;83:415-420.Full text external link opens in a new windowAbstract external link opens in a new window

28. Centers for Disease Control and Prevention. Highly pathogenic Asian avian influenza A (H5N1) virus. May 2018 [internet publication].Full text external link opens in a new window

29. Food and Agriculture Organization of the United Nations. Update on the continuous spread and expansion of H5N1 highly pathogenic avian influenza: clade 2.3.2.1 in Asia (2010-2012). January 2014 [internet publication].Full text external link opens in a new window

30. Centers for Disease Control and Prevention. Highly pathogenic avian influenza A (H5N1) in birds and other animals. April 2017 [internet publication].Full text external link opens in a new window

31. Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9:e1003657.Full text external link opens in a new windowAbstract external link opens in a new window

32. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, et al. Investigation of avian influenza (H5N1) outbreak in humans: Thailand, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(suppl 1):3-6.Full text external link opens in a new windowAbstract external link opens in a new window

33. Dinh PN, Long HT, Tien NT, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis. 2006;12:1841-1847.Full text external link opens in a new windowAbstract external link opens in a new window

34. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2011. WHO Wkly Epidemiolog Rec. 2012;87:117-128.Full text external link opens in a new window

35. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis. 1999;180:505-508.Abstract external link opens in a new window

36. Zhou L, Liao Q, Dong L, et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis. 2009;199:1726-1734.Abstract external link opens in a new window

37. Wan XF, Dong L, Lan Y, et al. Indications that live poultry markets are a major source of human H5N1 influenza virus infection in China. J Virol. 2011;85:13432-13438.Full text external link opens in a new windowAbstract external link opens in a new window

38. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet. 2008;372:744-749.Abstract external link opens in a new window

39. Horby P, Sudoyo H, Viprakasit V, et al. What is the evidence of a role for host genetics in susceptibility to influenza A/H5N1? Epidemiol Infect. 2010;138:1550-1558.Full text external link opens in a new windowAbstract external link opens in a new window

40. Human cases of avian influenza A (H5N1) in North-West Frontier Province, Pakistan, October-November 2007. Wkly Epidemiol Rec. 2008;83:359-364.Abstract external link opens in a new window

41. Aditama TY, Samaan G, Kusriastuti R, et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. Clin Infect Dis. 2011;53:1237-1244.Full text external link opens in a new windowAbstract external link opens in a new window

42. Aditama TY, Samaan G, Kusriastuti R, et al. Avian influenza H5N1 transmission in households, Indonesia. PLoS One. 2012;7:e29971.Full text external link opens in a new windowAbstract external link opens in a new window

43. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006;355:2186-2194.Full text external link opens in a new windowAbstract external link opens in a new window

44. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374-1385.Full text external link opens in a new windowAbstract external link opens in a new window

45. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012;486:420-428.Full text external link opens in a new windowAbstract external link opens in a new window

46. Neumann G, Macken CA, Karasin AI, et al. Egyptian H5N1 influenza viruses-cause for concern? PLoS Pathog. 2012;8:e1002932.Full text external link opens in a new windowAbstract external link opens in a new window

47. Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science. 2012;336:1541-1547.Full text external link opens in a new windowAbstract external link opens in a new window

48. Uyeki TM, Bresee JS. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis. 2007;13:1969-1971.Full text external link opens in a new windowAbstract external link opens in a new window

49. Refaey S, Azziz-Baumgartner E, Amin MM, et al. Increased number of human cases of influenza virus A(H5N1) infection, Egypt, 2014-15. Emerg Infect Dis. 2015;21:2171-2173.Full text external link opens in a new windowAbstract external link opens in a new window

50. Le MQ, Horby P, Fox A, et al. Subclinical avian influenza A(H5N1) virus infection in human, Vietnam. Emerg Infect Dis. 2013;19:1674-1677.Full text external link opens in a new windowAbstract external link opens in a new window

51. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197-201.Full text external link opens in a new windowAbstract external link opens in a new window

52. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005;3:591-600.Abstract external link opens in a new window

53. Yamada S, Suzuki Y, Suzuki T, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature. 2006;444:378-382.Abstract external link opens in a new window

54. van Riel D, Munster VJ, de Wit E, et al. H5N1 virus attachment to lower respiratory tract. Science. 2006;312:399.Full text external link opens in a new windowAbstract external link opens in a new window

55. Shu Y, Li CK, Li Z, et al. Avian influenza A(H5N1) viruses can directly infect and replicate in human gut tissues. J Infect Dis. 2010;201:1173-1177.Abstract external link opens in a new window

56. Chandrasekaran A, Srinivasan A, Raman R, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 2008;26:107-113.Abstract external link opens in a new window

57. Auewarakul P, Suptawiwat O, Kongchanagul A, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol. 2007;81:9950-9955.Full text external link opens in a new windowAbstract external link opens in a new window

58. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res. 2005;6:135.Full text external link opens in a new windowAbstract external link opens in a new window

59. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203-1207.Abstract external link opens in a new window

60. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet. 2007;370:1137-1145.Abstract external link opens in a new window

61. Cavailler P, Chu S, Ly S, et al. Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. J Clin Virol. 2010;48:123-126.Abstract external link opens in a new window

62. Apisarnthanarak A, Erb S, Stephenson I, et al. Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center. Clin Infect Dis. 2005;40:e16-e18.Abstract external link opens in a new window

63. Liem NT, Lim W. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis. 2005;11:210-215.Full text external link opens in a new windowAbstract external link opens in a new window

64. Schultsz C, Dong VC, Chau NV, et al. Avian influenza H5N1 and healthcare workers. Emerg Infect Dis. 2005;11:1158-1159.Full text external link opens in a new windowAbstract external link opens in a new window

65. World Health Organization. WHO laboratory biosafety guidelines for handling specimens suspected of containing avian influenza A virus. January 2005 [internet publication].Full text external link opens in a new window

66. Ortiz JR, Katz MA, Mahmoud MN, et al. Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006. J Infect Dis. 2007;196:1685-1691.Abstract external link opens in a new window

67. Prieto-Lara E, Llanos-Mendez A. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature. Vaccine. 2010;28:4328-4334.Abstract external link opens in a new window

68. Vesikari T, Forstén A, Herbinger KH, et al. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine. 2012;30:1388-1396.Abstract external link opens in a new window

69. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011;203:1729-1738.Full text external link opens in a new windowAbstract external link opens in a new window

70. US Food and Drug Administration. Influenza virus vaccine, H5N1 (for national stockpile). February 2018 [internet publication].Full text external link opens in a new window

71. Qualls N, Levitt A, Kanade N, et al; CDC Community Mitigation Guidelines Work Group. Community mitigation guidelines to prevent pandemic influenza - United States, 2017. MMWR Recomm Rep. 2017;66:1-34.Full text external link opens in a new windowAbstract external link opens in a new window

72. Centers for Disease Control and Prevention. Interim guidance for specimen collection, processing, and testing for patients with suspected infection with novel influenza A viruses associated with severe disease in humans. January 2016 [internet publication].Full text external link opens in a new window

73. World Health Organization. Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection. October 2006 [internet publication].Full text external link opens in a new window

74. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. August 2007 [internet publication].Full text external link opens in a new window

75. World Health Organization. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. August 2007 [internet publication].Full text external link opens in a new window

76. World Health Organization. WHO criteria for accepting positive PCR test results of H5 infection in humans from national reference laboratories. May 2011 [internet publication].Full text external link opens in a new window

77. World Health Organization. WHO accepts positive PCR test results of H5 infection in humans from the following laboratories. May 2011 [internet publication].Full text external link opens in a new window

78. World Health Organization. WHO reference laboratories for diagnosis of influenza A/H5 infection. May 2017 [internet publication].Full text external link opens in a new window

79. Powell TJ, Fox A, Peng Y, et al. Identification of H5N1-specific T-cell responses in a high-risk cohort in Vietnam indicates the existence of potential asymptomatic infections. J Infect Dis. 2012;205:20-27.Abstract external link opens in a new window

80. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red book: 2006 report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:561.

81. Centers for Disease Control and Prevention. Interim guidance on case definitions for investigations of human infection with highly pathogenic avian influenza A (H5N1) virus in the United States. January 2016 [internet publication].Full text external link opens in a new window

82. World Health Organization. WHO case definitions for human infections with influenza A(H5N1) virus. August 2006 [internet publication].Full text external link opens in a new window

83. Schunemann HJ, Hill SR, Kakad M, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7:21-31.Abstract external link opens in a new window

84. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. February 2010 [internet publication].Full text external link opens in a new window

85. World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. June 2006 [internet publication].Full text external link opens in a new window

86. Centres for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. March 2017 [internet publication].Full text external link opens in a new window

87. Patel RB, Mathur MB, Gould M, et al. Demographic and clinical predictors of mortality from highly pathogenic avian influenza A (H5N1) virus infection: CART analysis of international cases. PLoS One. 2014;9:e91630.Full text external link opens in a new windowAbstract external link opens in a new window

88. Arabi Y, Gomersall CD, Ahmed QA, et al. The critically ill avian influenza A (H5N1) patient. Crit Care Med. 2007;35:1397-1403.Abstract external link opens in a new window

89. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 2010;202:1154-1160.Full text external link opens in a new windowAbstract external link opens in a new window

90. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012;206:1359-1366.Abstract external link opens in a new window

91. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667-2672.Full text external link opens in a new windowAbstract external link opens in a new window

92. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437:1108.Abstract external link opens in a new window

93. Le MT, Wertheim HF, Nguyen HD, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS One. 2008;3:e3339.Full text external link opens in a new windowAbstract external link opens in a new window

94. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7:e1000362.Full text external link opens in a new windowAbstract external link opens in a new window

95. World Health Organization. Infection control recommendations for avian influenza in health-care facilities. 2006 [internet publication].Full text external link opens in a new window

96. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. February 2018 [internet publication].Full text external link opens in a new window

97. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2013-2014. Pediatrics. 2013;132:e1089-e1104.Full text external link opens in a new windowAbstract external link opens in a new window

98. Kayali G, Webby RJ, Ducatez MF, et al. The epidemiological and molecular aspects of influenza H5N1 viruses at the human-animal interface in Egypt. PLoS One. 2011;6:e17730.Full text external link opens in a new windowAbstract external link opens in a new window

99. Fiebig L, Soyka J, Buda S, et al. Avian influenza A(H5N1) in humans: new insights from a line list of World Health Organization confirmed cases, September 2006 to August 2010. Euro Surveill. 2011;16:19941.Abstract external link opens in a new window

100. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One. 2008;3:e3410.Full text external link opens in a new windowAbstract external link opens in a new window

101. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450-1451.Full text external link opens in a new windowAbstract external link opens in a new window

102. Yu H, Gao Z, Feng Z, et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One. 2008;3:e2985.Full text external link opens in a new windowAbstract external link opens in a new window

103. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J infect Dis. 2015;211:80-90.Full text external link opens in a new windowAbstract external link opens in a new window

104. Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011;9:851-857.Abstract external link opens in a new window

105. Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008;52:3889-3897.Full text external link opens in a new windowAbstract external link opens in a new window

106. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy. 2007;27:494-503.Abstract external link opens in a new window

107. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492-500.Abstract external link opens in a new window

108. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1infection. Clin Infect Dis. 2011;53:326-333.Abstract external link opens in a new window

109. Lee CM, Hudson LD. Long-term outcomes after ARDS. Semin Respir Crit Care Med. 2001;22:327-336.Abstract external link opens in a new window

110. Ehlenbach WJ, Hough CL, Crane PK, et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA. 2010;303:763-770.Full text external link opens in a new windowAbstract external link opens in a new window